Chemical Name: (6α,11β,16α)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione
Molecular Formula: C24H30F2O6
CAS Number: 67-73-2
Synthetic fluorinated corticosteroid.
Uses for Fluocinolone (EENT)
Management of chronic noninfectious uveitis affecting the posterior segment of the eye (designated an orphan drug by FDA for this use).
Fluocinolone (EENT) Dosage and Administration
Surgically implant intravitreally through a pars plana incision into posterior segment of eye.
Maintain aseptic technique prior to and during the procedure to ensure sterility of the surgical field and implants. Do not resterilize implants by any method.
Handle implants only by the suture tab to avoid damaging the implant; damage may increase rate of drug release.
Avoid simultaneous implantation into both eyes in order to minimize risk of bilateral postoperative infections.
Following depletion of fluocinolone acetonide from the implant, may remove the implant and replace with a new one to continue therapy.
During implantation and explantation, avoid applying sheer forces on the implant that could disengage the silicone cup reservoir from the suture tab.
Available as fluocinolone acetonide; dosage expressed in terms of the salt.
Children ≥12 years of age: 0.59 mg (1 implant) in affected eye(s) approximately every 30 months.
0.59 mg (1 implant) in affected eye(s) approximately every 30 months.
Cautions for Fluocinolone (EENT)
Viral diseases of the cornea and conjunctiva (e.g., epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella).
Mycobacterial infection of the eye.
Fungal diseases of ocular structures.
Known or suspected hypersensitivity to fluocinolone acetonide, other corticosteroids, or any ingredient in the formulation.
Potential complications accompanying insertion of the implant may include cataract formation, choroidal or retinal detachment, temporary decrease in visual acuity, endophthalmitis, hypotony, increased intraocular pressure (IOP), exacerbation of intraocular inflammation, vitreous hemorrhage, vitreous loss, and wound dehiscence.
Immediate and temporary decrease in visual acuity in the implanted eye will occur in most patients and may persist for 1–4 weeks after implantation.
Increased Intraocular Pressure
Risk of glaucoma with prolonged use of corticosteroids; monitor periodically for elevated IOP (e.g., every 3–6 months, more frequently in immediate postimplantation period). Use with caution in the presence of glaucoma.
Approximately 60% of patients expected to require drug therapy to reduce IOP within 34 weeks after implantation. Within 2 years of implantation, 32% of patients expected to require filtering procedures for IOP control.
Risk of prolongation or exacerbation of ocular viral infections (e.g., herpes simplex) with ophthalmic corticosteroids. Use with extreme caution in patients with history of herpes simplex.
Risk of secondary ocular infection (bacterial, fungal, or viral) with prolonged use of corticosteroids. Consider possibility of fungal infection if persistent corneal ulceration occurs.
In acute purulent conditions, corticosteroids may mask or enhance existing infections.
Wound Healing Complications
Use of ophthalmic corticosteroids after cataract surgery may delay healing and increase bleb formation.
Proper Handling of Implants
Exercise caution in order to maintain sterility of and avoid damage to the implant. (See Administration under Dosage and Administration.)
Caution if used in nursing women. Not known whether ocular administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in milk.
Systemically administered corticosteroids appear in milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other adverse effects.
Safety and efficacy not established in children <12 years of age.
No substantial differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Cataracts, increased IOP, ocular pain, and surgical complications (e.g., cataract fragments in the eye, injury, mechanical complications, migration or expulsion of implant; wound complications or wound dehiscence) reported in 50–90% of patients.
Reduced visual acuity, conjunctival hemorrhage or hyperemia, glaucoma, blurred vision, abnormal sensation in the eye, ocular irritation or inflammation, hypotony, pruritus, vitreous floaters or hemorrhage, ptosis, maculopathy, eyelid edema, increased tearing, and dry eye reported in 10–35% of patients.
Headache was most frequent systemic effect.
Interactions for Fluocinolone (EENT)
No formal drug interaction studies have been performed to date. However, because of limited systemic exposure, only intraocular interactions would be expected.
Fluocinolone (EENT) Pharmacokinetics
Implant is designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 mcg daily, decreasing over the first month to steady state of 0.3–0.4 mcg daily for approximately 30 months.
Concentrations of the drug in aqueous and vitreous humor highly variable
Limited systemic exposure following intravitreal implantation; plasma concentrations are usually undetectable.
15–25°C. Protect from freezing.
Corticosteroids inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary and fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
Mechanism of ocular effects is unknown. Corticosteroids may induce phospholipase A2 inhibitory proteins; these proteins may inhibit release of arachidonic acid, thus controlling biosynthesis of potent mediators of inflammation (e.g., prostaglandins, leukotrienes).
Advice to Patients
Importance of informing patients that fluocinolone acetonide treats ocular inflammation only and does not treat underlying disease.
Importance of advising patients to return to clinician’s office for follow-up ophthalmologic examinations of both eyes at appropriate intervals following insertion of the implant.
Importance of explaining risks of surgical complications, adverse ocular effects, and ocular infections.
Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses, especially glaucoma or existing bacterial, viral, or fungal infections of the eye.
Importance of informing patients of other important precautionary information. (See Cautions.)
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Bausch & Lomb
AHFS DI Essentials™. © Copyright 2022, Selected Revisions June 1, 2006. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
Frequently asked questions
More about fluocinolone ophthalmic
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 7 Reviews
- Drug class: ophthalmic steroids